AstraZeneca Shares Hit Record High After Earnings Beat, U.S. Price Deal -- Market Talk
Dow Jones
Yesterday
1338 GMT - AstraZeneca shares hit their highest level on record after third-quarter earnings last week beat market expectations. A U.S. drug-pricing deal reached last month that eased policy uncertainty also supports gains for the British pharma group, which makes more than 40% of its sales in the U.S. Shares rose 2.5% in early trading after climbing to an all-time intraday high of 134.6 pounds. Shares are now trading at 133.48 pounds, valuing the company at 203.3 billion pounds. AstraZeneca remains the largest U.K.-listed stock by market capitalization. (william.gray@wsj.com)
(END) Dow Jones Newswires
November 11, 2025 08:38 ET (13:38 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
At the request of the copyright holder, you need to log in to view this content
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.